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GSK3b Inhibition Blocks Melanoma Cell/Host
Interactions by Downregulating N-Cadherin
Expression and Decreasing FAK Phosphorylation
Jobin K. John1, Kim H.T. Paraiso1, Vito W. Rebecca1, Liliana P. Cantini1, Ethan V. Abel2,
Nicholas Pagano3,4, Eric Meggers3,4, Rahel Mathew5, Clemens Krepler6, Victoria Izumi7, Bin Fang7,
John M. Koomen1, Jane L. Messina5, Meenhard Herlyn6 and Keiran S.M. Smalley1,8
This study addresses the role of glycogen synthase kinase (GSK)-3b signaling in the tumorigenic behavior of
melanoma. Immunohistochemical staining revealed GSK3b to be focally expressed in the invasive portions of 12
and 33% of primary and metastatic melanomas, respectively. GSK3 inhibitors and small interfering RNA (siRNA)
knockdown of GSK3b were found to inhibit the motile behavior of melanoma cells in scratch wound, three-
dimensional collagen–implanted spheroid, and modified Boyden chamber assays. Functionally, inhibition of
GSK3b signaling was found to suppress N-cadherin expression at the messenger RNA and protein levels, and
was associated with decreased expression of the transcription factor Slug. Pharmacological and genetic ablation
of GSK3b signaling inhibited the adhesion of melanoma cells to both endothelial cells and fibroblasts and
prevented transendothelial migration, an effect rescued by the forced overexpression of N-cadherin. A further
role for GSK3b signaling in invasion was suggested by the ability of GSK3b inhibitors and siRNA knockdown to
block phosphorylation of focal adhesion kinase (FAK) and increase the size of focal adhesions. In summary,
we have, to our knowledge, demonstrated a previously unreported role for GSK3b in modulating the motile
and invasive behavior of melanoma cells through N-cadherin and FAK. These studies suggest the potential
therapeutic utility of inhibiting GSK3b in defined subsets of melanoma.
Journal of Investigative Dermatology (2012) 132, 2818–2827; doi:10.1038/jid.2012.237; published online 19 July 2012
INTRODUCTION
Glycogen synthase kinase (GSK)-3b is a serine/threonine
kinase that is present at the junction of the PI3K/AKT and Wnt
signaling pathways (Cohen and Frame, 2001). Its activity is
inhibited by AKT, which phosphorylates and inactivates the
kinase (Cross et al., 1995). GSK-3b has a critical role in the
regulation of canonical Wnt signaling by directly phosphor-
ylating b-catenin, leading in turn to its proteasomal targeting
and subsequent degradation (Yost et al., 1996). Although
increased Wnt/b-catenin signaling has been implicated in
oncogenesis (He et al., 1998; Camilli and Weeraratna, 2010),
there is currently little evidence that inhibition of GSK3b
contributes to melanoma progression (Chien et al., 2009;
Arozarena et al., 2011).
In addition to its role in Wnt survival signaling, b-catenin
is also expressed at adherens junctions, where it facilitates
cell–cell adhesion through an association with E-cadherin
and N-cadherin (Smalley et al., 2005; Harris and Tepass,
2010). Adherens junctions have been best studied in
epithelial tissues in which they are known to be critical
for the maintenance of cellular architecture (Lioni et al.,
2007). Of relevance to melanoma, both melanocytes
and skin keratinocytes express E-cadherin, and there is
evidence that homotypic E-cadherin signaling constitutes a
major regulatory mechanism of the ‘‘epidermal melanin
unit’’ in normal skin (Hsu et al., 2000b; Haass et al., 2005).
Loss of E-cadherin expression is often viewed as a first step
in melanoma progression that allows transformed
melanocytes to escape from local keratinocyte control
(Li et al., 2001). In melanoma development, E-cadherin loss
is typically accompanied by an increase in N-cadherin
expression that facilitates tumor cell dissemination by
increasing the interaction of melanoma cells with host
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endothelial cells and fibroblasts, as well as increasing
melanoma cell survival (Li et al., 2001, 2003).
Very little is currently known about the function of
GSK3b signaling in melanoma. Here we present new data
demonstrating that low constitutive levels of GSK3b signaling
contribute to the oncogenic behavior of melanoma by
regulating both N-cadherin expression and focal adhesion
complexes. For these studies, we used a highly potent
organometallic kinase inhibitor of GSK3b (IC50 0.3 nM)
(Pagano et al., 2007; Atilla-Gokcumen et al., 2008) to
show that inhibition of GSK3b signaling limits the motile
and invasive behavior of melanoma cells through a mechan-
ism associated with decreased Slug expression. We
also provide evidence that inhibition of GSK3b abrogates
the interaction of melanoma cells with host fibroblasts and
endothelial cells.
RESULTS
GSK3b inhibition blocks the migration and invasion of
melanoma cell lines
Western blotting revealed GSK3b to be constitutively
phosphorylated at Ser9 in nearly all of the melanoma cell
lines tested (Supplementary Figure S1A online). No correla-
tion was noted between phospho-GSK3b expression and the
presence of either BRAF or an NRAS mutation or PTEN
expression (Supplementary Table S1 online and not shown).
Treatment of melanoma cell lines with NP309 (300 nM) and
another structurally unrelated GSK3b inhibitor (LiCl) led to
increased b-catenin expression (Supplementary Figure S2
online), demonstrating the presence of an activated GSK3b
pool. Analysis of melanoma lesions (n¼ 40) showed GSK3b
and phospho-GSK3b to be expressed in both primary (5/16)
and metastatic specimens (8/24). The strongest staining was
noted to be focal and located to the leading edge areas of the
tumor, where the tumor and stroma were interacting (Figure
1a–c; Supplementary Figure S3 online). In primary melano-
ma, the strongest GSK3b staining was located at the invasive
front, with fewer primary samples exhibiting strong focal
staining (2/16) than metastatic samples (8/24). As the leading
edge is the area where invasion occurs, we next asked
whether GSK3b signaling was required for melanoma cell
migration and invasion.
NP309 prevents the migration and invasion of melanoma cell
lines
Treatment of the WM793, 1205Lu, and WM9 melanoma cell
lines with the GSK3b inhibitors NP309 and LiCl and small
interfering RNA (siRNA) knockdown of GSK3b inhibited the
motile behavior of melanoma cells in a scratch wound assay
(Figure 2a and b: Supplementary Figure S4 online). NP309
and LiCl also prevented the invasion of 1205Lu, WM9, and
WM793 melanoma cells in a modified Boyden chamber
assay, as well as the invasion of spheroids into a collagen gel
(Figure 2c and d; Supplementary Figure S5 online). Treatment
of melanoma cells with NP309 for 24 hours did not affect the
growth of the melanoma cells (Supplementary Figure S6
online), suggesting that the observed effects on invasion were
not the result of reduced cell proliferation.
Inhibition of GSK3b signaling in melanoma cells reduces
N-cadherin expression
Previous work from our group has shown that increased
N-cadherin expression increases the migratory behavior
of melanoma cells (Li et al., 2001). Treatment of melanoma
cells with increasing concentrations of NP309 or LiCl led to
biphasic effects upon the Ser33/Ser37/Thr41 phosphorylation
of b-catenin (an increase at lower concentrations followed by
a decrease at higher NP309 concentrations), an upregulation
of total b-catenin expression (and its localization to the
nucleus), and a reduction in N-cadherin expression (Figure 3a
and b: Supplementary Figures S7 and S8 online). The effects
of NP309 upon N-cadherin expression were GSK3b depen-
dent, and could be recapitulated following siRNA knock-
down of GSK3b expression (Figure 3c). We next used mass
spectrometry to demonstrate that GSK3b inhibition did not
posttranslationally modify N-cadherin (no changes were
observed in ubiquitination, acetylation, phosphorylation,
and methylation) (Supplementary Figure S9 online). Instead,
it was noted that NP309 reduced N-cadherin expression
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Figure 1. Glycogen synthase kinase (GSK)-3b is focally expressed in
melanoma specimens. (a) Representative immunohistochemical staining of an
invasive primary melanoma and a melanoma brain metastases for expression
of total GSK3b and phospho-GSK3b. Bar¼ 250 mm. Inset: arrows indicate
focal expression of GSK3b. Bar¼ 100mm. (b) The number of primary and
metastatic melanoma specimens with high levels (þ 2/3) of focal staining for
GSK3b. (c) High-power images of two melanoma metastases, showing
increased levels of total GSK3b staining at the invasive front. M, melanoma;
S, stroma.
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at the messenger RNA level (Figure 3d), and decreased
the expression of the epithelial-to-mesenchymal transition
(EMT)–associated transcription factor Slug (Figure 3e). In
agreement with the GSK3b inhibitor partly reversing the
‘‘EMT-like’’ state of melanoma cells, NP309 also reduced
the expression of fibronectin at both the RNA and protein
levels (Figure 3f and g). No changes were noted in the
expression of E-cadherin, Vimentin, Twist, or Snail (Figure 3e
and not shown).
Inhibition of GSK3b signaling prevents melanoma cell adhesion
to fibroblasts and endothelial cells, and transendothelial
migration
Previous work from our group demonstrated that N-cadherin
is important for the interaction of melanoma cells with host
fibroblasts and endothelial cells (Li et al., 2001; Smalley
et al., 2005). In agreement with these findings, we observed
that the pretreatment of DiI-labeled 1205Lu, WM793, and
WM9 cells with NP309 or LiCl prevented adhesion onto a
fully confluent monolayer of human skin fibroblasts and
endothelial cells (Figure 4a and data not shown). These
effects were partly N-cadherin mediated and could be
recapitulated by siRNA knockdown of N-cadherin expression
(Supplementary Figure S10 online), and partly rescued
following the overexpression of N-cadherin (Figure 4b).
Pharmacological inhibition and siRNA knockdown of GSK3b
also inhibited the migration of 1205Lu, WM793, and WM9
melanoma cells through an activated, confluent endothelial
cell monolayer (Figure 4c and d). Again, these effects were
N-cadherin-dependent and could be rescued following the
overexpression of N-cadherin (Figure 4e).
Inhibition of GSK3b increases the size of focal adhesions
Studies in colorectal and pancreatic cancer suggest that
GSK3b modulates cell migration and invasion through the
regulation of focal adhesion assembly (Kobayashi et al.,
Time 0a
b
d
c
Control
NP309
1205Lu
100
80
Mock NT siGSK3
GSK3
GAPDH
**
**
**
**
*
*
*
60
%
 D
is
ta
nc
e
D
is
ta
nc
e 
(%
)
%
 In
va
si
on
40
20
0
100
80
WM9
WM9
WM9
1205Lu
1205Lu
1205Lu
WM793
WM793
65.2% 53.7%92.0%
WM793
NP309
LiCl
Control
60
120
40
20
0
100
80
***
**
***
*
*
60
120
40
20
0
Mock Control
Control
Control
NP
0.1 µM
0.1 µM
0.3 µM
0.3 µM
100 µm
NT siGSK3
Viability ImageJ analysis
24 Hours
Figure 2. Glycogen synthase kinase (GSK)-3b inhibition prevents the migration and invasion of melanoma cell lines. (a) NP309 (0.3 mM) and LiCl (50mM)
prevent the movement of melanoma cells into a scratch wound. (b) Small interfering RNA (siRNA) knockdown of GSK3b prevents the movement of 1205Lu
melanoma cells into the scratch. Western blot shows knockdown of GSK3b (Mock: no siRNA; NT: scrambled control and GSK3b siRNA). (c) NP309 prevents the
invasion of melanoma cells in a modified Boyden chamber model. (d) NP309 (0.3 and 1 mM, 48 hours) prevents the invasion of melanoma cells in a three-
dimensional collagen–implanted spheroid model. Bar¼100 mm. Images were analyzed using ImageJ. Statistically significant differences from controls are
indicated, where *Po0.05, **Po0.01, ***Po0.005. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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2006). We next determined whether the inhibition of GSK3b
also regulated focal adhesion kinase (FAK) activity. Using
WM793 melanoma cells that express enhanced green
fluorescent protein (EGFP)-FAK, and 1205Lu cells stained
for total FAK, we demonstrated that NP309 treatment and
siRNA knockdown of GSK3b increased the number of large
focal adhesions as shown by increased staining for FAK
(Figure 5), paxillin, and vinculin (Supplementary Figure S11
online).
NP309 inhibits FAK signaling in melanoma cells, leading to the
inhibition of motility and invasion
Treatment of WM9, WM793, and 1205Lu melanoma cell
lines with increasing concentrations of NP309 inhibited FAK
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Figure 3. Inhibition of glycogen synthase kinase (GSK)-3b leads to a reduction in N-cadherin expression. (a) Western blot showing NP309 increases b-catenin
expression and decreases N-cadherin expression in melanoma cells. (b) Immunofluorescence pictures demonstrating the ability of NP309 to increase membrane
and nuclear b-catenin expression in WM793 cells. Arrows indicate areas of b-catenin expression at cell-cell junctions. Bar¼50 mm. (c) Small interfering
RNA (siRNA) knockdown of GSK3b reduces N-cadherin expression in WM793 cells. (d) NP309 (0.3 mM, 24 hours) decreases N-cadherin expression at the
messenger RNA (mRNA) level. (e) NP309 decreases the expression of Slug. (f) (top panel) Western blot showing NP309 (0–0.1 mM, 24 hours) decreases the
expression of fibronectin (bottom panel). Immunofluorescence staining showing decreased fibronectin expression following NP309 (0.3 mM, 24 hours) treatment.
(g) NP309 (0.3 mM, 24 hours) decreases fibronectin expression at the mRNA level. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. **Po0.01;
***Po0.005.
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phosphorylation at the Tyr397 activation site (Figure 6a). A
comprehensive mass spectrometry–based analysis of FAK
phosphorylation demonstrated that GSK3b inhibition in-
creased the phosphorylation of FAK at Ser843, an inhibitory
phosphorylation site (Jacamo et al., 2007; Supplementary
Figure S12 online). The requirement for FAK in the motile and
invasive behavior of melanoma cells was demonstrated by
the ability of a FAK inhibitor (PF-228, 10 mM) to inhibit the
movement of cells into a scratch wound and to reduce the
invasion of 1205Lu, WM793, and WM9 melanoma cells in
modified Boyden chamber and three-dimensional collagen–
implanted spheroid assays (Figure 6b–d).
DISCUSSION
Strategies to prevent the metastatic spread of melanoma are
currently lacking. Here, we demonstrate that the inhibition
of GSK3b signaling limits the motile and invasive behavior
of melanoma cells and prevents some of the host/tumor
interactions required for the transit of melanoma through the
dermal microenvironment and into the vasculature.
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Since its initial identification as an enzyme involved in the
regulation of glycogen synthesis in response to insulin
signaling, GSK3b has been implicated in a wide range of
physiological processes ranging from protein synthesis to
subcellular protein localization (Cohen and Frame, 2001;
Frame and Cohen, 2001). A role for GSK3b signaling in
cancer development and progression is suggested by its role
in the phosphorylation of cyclin D1 and its ability to control
Wnt signaling through the phosphorylation and degradation
of b-catenin (Diehl et al., 1998). GSK3b is negatively
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Figure 5. Glycogen synthase kinase (GSK)-3b regulates focal adhesions in melanoma cells. Inhibition of GSK3b and small interfering RNA (siRNA) knockdown
of GSK3b increases the size of focal adhesions in WM793 and 1205Lu melanoma cells. Doxycycline-inducible enhanced green fluorescent protein-
FAK–expressing WM793 and parental 1205Lu cells were treated with vehicle (control), scrambled siRNA control (Scr), NP309 (0.3 mM), or an siRNA against
GSK3b. WM793 were imaged directly, and 1205Lu cells were fixed and stained for focal adhesion kinase (FAK) expression. Bar¼25 mm.
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regulated by the serine/threonine kinase AKT through its
phosphorylation at Ser9 (Cross et al., 1995). Most melanomas
are known to have constitutive activity in AKT that results
from increased expression of AKT3, constitutive activation of
receptor tyrosine kinase signaling, or through deregulation
of the negative pathway regulator PTEN (Stahl et al., 2004;
Tsao et al., 2004; Davies et al., 2008; Paraiso et al., 2011).
Given that AKT inactivates GSK3b signaling, the potentially
oncogenic role of GSK3b in melanoma has been little
considered.
Immunostaining of melanoma tissue specimens showed
that GSK3b was focally expressed and mostly localized at the
leading edge, suggesting a role for this pathway in melanoma
invasion. Although high, focal GSK3b expression was not
restricted to melanoma metastases, it was noted that the
strongest GSK3b staining observed in primary melanomas
was located in nests of cells at the periphery of the tumor,
where dermal invasion was occurring. In other tissue systems,
there is already good evidence for the involvement of GSK3b
in the control of cellular polarity and cytoskeletal architec-
ture. In neuronal growth cones, GSK3b localizes to the
invasive front and regulates the microtubule assembly
required for cell motility and polarity (Eickholt et al., 2002;
Gartner et al., 2006). GSK3b signaling is also required for the
formation of lamellipodia in migrating keratinocytes, as well
as the directional motility of skin stem cells during wound
healing (Koivisto et al., 2003; Wu et al., 2011).
Tumor development and metastasis requires the continual
bidirectional interaction between host and tumor cells
(Bhowmick et al., 2004a,b; Gaggioli et al., 2007). The
progression of melanoma is often associated with a cadherin
switch, in which E-cadherin expression is downregulated
allowing nascent melanoma cells to escape from the control
of the skin keratinocytes (Hsu et al., 2000a,b). Melanoma
cells then change binding partners and associate instead with
stromal fibroblasts and endothelial cells (Li et al., 2003). The
interaction of melanoma cells with endothelial cells is likely
to be particularly important when melanomas disseminate
through the vasculature, such as during the seeding of
metastases into the brain. Previous studies have indicated that
the adhesion of melanoma cells to endothelial cells and their
subsequent transendothelial migration is dependent upon
homotypic N-cadherin binding (Li et al., 2001; Qi et al.,
2005). In agreement with a role for GSK3b signaling in the
regulation of N-cadherin expression, NP309 treatment
blocked the adhesion of melanoma cells onto a confluent
endothelial cell layer and prevented the transendothelial
migration of melanoma cells. The role for N-cadherin in both
of these processes was demonstrated by the ability of forced
N-cadherin expression to rescue the inhibitory effects of
NP309 upon adhesion and transendothelial cell migration.
From a mechanistic standpoint, GSK3b was found to
regulate N-cadherin expression at the messenger RNA level,
and GSK3b inhibition was associated with the decreased
expression of Slug, a Snail-family transcription factor
implicated in the metastatic behavior of melanoma cells
(Gupta et al., 2005). The potential role of Slug down-
regulation in the anti-migratory effects of GSK3b inhibition is
supported by recent studies showing that overexpression of
Slug in melanocytes increases N-cadherin expression, lead-
ing to an enhancement of cell motility (Shirley et al., 2012).
Taken together, these data suggest a potential role for GSK3b
signaling in the transcriptional program required for melano-
ma dissemination.
The disruption of homotypic N-cadherin signaling follow-
ing GSK3b inhibition is likely to have other beneficial effects.
The engagement of N-cadherin signaling in melanoma cells
is known to activate the AKT pathway, leading to increased
cell survival (Li et al., 2001). It is possible that the interaction
of melanoma cells with fibroblasts through N-cadherin
contributes to this survival as demonstrated by the reduced
cisplatin-induced apoptotic response observed in melanoma
cells following their adhesion to fibroblasts (Flach et al.,
2011). The potential clinical relevance of these findings has
already been suggested by the observation that inhibition of
N-cadherin signaling enhances chemotherapy sensitivity in
melanoma patients undergoing isolated limb infusion (Li
et al., 2001; Beasley et al., 2011).
The coordinated movement of invading cells involves
adhesion and membrane protrusion at the leading edge, and
detachment and retraction at the trailing edge. As GSK3b was
primarily expressed at the invasive front of melanoma
specimens, we asked whether GSK3b was involved in
melanoma cell adhesion. As our focus, we studied FAK, a
kinase known to occupy a central position linking integrin-
mediated adhesion to the downstream activation of key
signaling pathways involved in cytoskeletal rearrangement
and survival. It was observed that NP309 treatment inhibited
phosphorylation of FAK at its activating autophosphorylation
(Tyr397) site, and that a small-molecule FAK inhibitor (PF-228)
also prevented both the migration of melanoma cells in a
scratch wound assay and the invasion of the highly invasive
1205Lu and WM9 melanoma cell lines in Boyden chamber
and three-dimensional spheroid assays. Although our studies
did not demonstrate a direct link between GSK3b inhibition
and inhibition of FAK phosphorylation at Tyr397, a detailed
mass spectrometry analysis of FAK phosphorylation sites did
reveal NP309 treatment to enhance FAK phosphorylation at
Ser843, a site known to be associated with dephosphorylation
of FAK at Tyr397 (Jacamo et al., 2007). Studies are ongoing to
identify the candidate serine/threonine kinase that directly
phosphorylates FAK at Ser843 upon GSK3b inhibition.
GSK3b inhibition also led to an increase in the size of
focal adhesions. Our results mirrored those observed in HeLa
cells in which inhibition of GSK3b using both siRNA and
pharmacological inhibitors impaired cell motility and in-
creased the size and number of focal adhesions (Kobayashi
et al., 2006). Links between inhibition of FAK and impaired
motility have been reported by a number of other groups
with FAK-null fibroblasts being shown to have an
impaired migratory response associated with an increase in
adhesion strength and the size and number of focal
adhesions; the fact that constitutively activated FAK can
partially rescue the motile behavior of cells in which GSK3b
has been depleted has also been reported (Ilic et al., 1995;
Kobayashi et al., 2006).
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To our knowledge, the role of GSK3b in both the motile
behavior of melanoma cells and the interaction of melanoma
cells with host fibroblasts and endothelial cells has never
been previously reported. Further studies will be required to
determine whether GSK3b inhibition is a viable strategy to
limit the metastatic phenotype of melanoma in vivo.
MATERIALS AND METHODS
Cell culture and growth inhibition
Melanoma cells lines were grown as described in Paraiso et al.,
2010. The identity of the cell lines was confirmed using the Coriell
Institute (Camden, NJ) cell identity mapping kit.
Drugs and inhibitors
NP309 was synthesized and characterized for its anti-GSK3b activity
as described in Pagano et al., 2007. PF-228 and LiCl were purchased
from Sigma-Aldrich (St Louis, MO).
Immunohistochemical staining of melanoma specimens
Deidentified formalin-fixed paraffin-embedded tissue samples were
obtained from the Moffitt Pathology archives under a written
informed consent protocol approved by the Institutional Review
Board of the University of South Florida under the Declaration of
Helsinki Protocols and stained using the Ventana Discovery XT
automated system (Ventana Medical Systems, Tucson, AZ) (Paraiso
et al., 2011). The rabbit primary antibody for p-GSK3b was from Cell
Signaling Technology (Beverly, MA) and the antibody for total
GSK3b was from Epitomics (Burlingame, CA). Staining was
visualized using the Ventana Chromomap Redkit. Slides were
analyzed by two independent observers and consensus scored on
a scale from 0 to þ 3.
Western blotting
Proteins were extracted and blotted for as described in Smalley et al.,
2007. The antibodies to phospho-GSK3b (Ser9), total GSK3b,
phospho-FAK (Tyr 397), total FAK, phospho-b-catenin (Ser33/37/
Thr41), and vimentin were from Cell Signaling Technology. The
antibodies for fibronectin, N-cadherin, and total b-catenin were from
BD Biosciences (San Jose, CA). The antibodies for Twist and SLUG
were from Santa Cruz (Santa Cruz, CA), whereas the antibody for
Snail was from Abcam (Cambridge, MA). In all cases, western blots
were stripped once and probed for glyceraldehyde-3-phosphate
dehydrogenase or actin (Sigma-Aldrich) to confirm even protein
loading.
RNA interference
RNA interference experiments were performed as described in
Paraiso et al., 2011. Cells were treated with 25 nM N-cadherin
(Dharmacon, Lafayette, CO) and 20 nM GSK3b (Cell Signaling
Technology). In addition, scrambled siRNAs at each concentration
were also added as nontargeting controls.
Three-dimensional spheroid assays
Collagen-implanted spheroids were prepared using the liquid
overlay method (Smalley et al., 2006) and were treated with
0.3 mM NP309 or LiCl (50mM) for 24–72 hours before being analyzed
using a Nikon-TS100 (Melville, NY) inverted fluorescence micro-
scope and analyzed using ImageJ (NIH, Bethesda, MD).
Fibroblast/endothelial cell adhesion assays
Human skin fibroblasts (FF2554) or human vascular endothelial cells
were seeded out to 100% confluency and left to grow overnight.
1205Lu, WM793, and WM9 melanoma cells were labeled with DiI
before treatment with vehicle, NP309 (0.3 mM), GSK3 siRNA, or LiCl
(50mM) for 24 hours. Equal numbers of cells were then added to the
confluent fibroblast/endothelial cell monolayers and allowed to
adhere for 20minutes before being washed four times with fresh
media and quantified by counting five  20 fields.
Transendothelial cell migration assays
Human vascular endothelial cells were plated onto transwell inserts
and allowed to grow to confluence over 48 hours before being
activated with TNF-a (10 ngml1 24 hours). 1205Lu, WM793, and
WM9 cells were pretreated with NP309, LiCl, or siRNA to GSK3b or
scrambled control for 48 hours before being counted and tested for
viability by trypan blue staining. A total of 25,000 melanoma cells
were then DiI labeled and plated on top of the human vascular
endothelial cell layer in serum-free media with fetal bovine
serum–containing media added to the lower chamber. Following
1–4 hours of incubation, cotton swabs were used to remove
nonmigratory cells before fixation (4% paraformaldehyde) and
imaging with a Nikon Eclipse TS100 microscope.
Adenoviral vector infections
Cells were infected with 10–100 plaque forming units of adenovirus
encoding for N-cadherin as described in Li et al., 2001.
Scratch wound assays
Confluent monolayers of melanoma cells (1205Lu, WM793, and
WM9) were allowed to grow to confluence before being scratched
with a p10 pipette tip. Cultures were treated with vehicle, NP309,
LiCl (concentrations as above), or GSK3b siRNA (48 hours pretreat-
ment) before being imaged (1–24 hours). Percentage wound closure
was calculated using ImageJ.
Modified Boyden chamber assays
Invasion was measured in Chemotaxis Chambers (96-well format
from NeuroProbe (Gaithersburg, MD)) following coating with
Matrigel (BD, San Jose, CA). Briefly, cells were trypsinized, rinsed
twice with PBS, resuspended in serum-free media, and were loaded
on the upper chamber and allowed to invade through the Matrigel
toward 10% fetal bovine serum for 20 hours. Noninvasive cells were
removed, and the remaining cells were fixed and stained with
Crystal Violet with absorbance being read at OD 560 nm. For
loading control and to normalize for differences in cell proliferation,
cells were allowed to grow for the same time as the incubation in the
Boyden chambers, after which cells were stained with Crystal Violet.
Cells were quantified at OD 560nm after dye extraction, and this
number was used to normalize the invasion value.
EGFP-FAK–expressing cells
The EGFP-coding region and multiple cloning site were amplified
from pEGFP-C1 (Clontech, Mountainview, CA) and TOPO cloned
into pENTR/D-TOPO (Invitrogen, Grand Isle, NY). Chicken FAK was
subcloned from pBluescript-FAK (kindly provided by Dr Jihe Zhao,
University of Central Florida Burnett School of Biomedical Sciences)
into pENTR/D-TOPO/EGFP-MCS. The resulting pENTR/D-TOPO/
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EGFP-FAK was shuttled into pLenti4/TO/V5-DEST (Invitrogen) using
Gateway LR Clonase II (Invitrogen), which put the coding region in-
frame with the vectors C-terminal V5-epitope and stop codons.
pLenti4/TO/V5-GW/EGFP-FAK was packaged in HEK293FT cells
using Invitrogen’s ViraPower Lentiviral Packaging Mix and protocol,
with the substitution of 36 ml FuGENE HD (Roche, Nutley, NJ) for
Lipofectamine 2000 for the transfection. Medium containing
lentivirus particles was collected 72 hours post transfection and
added to WM793TR cells (Abel and Aplin, 2010) for 72 hours
followed by selection in Zeocin (100mgml1).
Immunofluorescence staining
Cells (WM793 or WM793-FAK, and 1205Lu) were plated onto
coverslips and treated for 24 hours before being fixed and permea-
bilized as previously described (Smalley et al., 2007) and imaged
with a Leica (Lawrenceville, GA) confocal microscope at  63. In
some cases, slides were stained for paxillin, vinculin, or fibronectin
(BD Pharmingen, San Jose, CA).
Quantitative real-time PCR
Cells were treated for 24 hours with 300 nM NP309 before RNA
isolation. Total RNA was isolated using Qiagen’s RNeasy mini kit
(Valencia, CA). The following TaqMan Gene Expression Assays
primer/probes were used: Hs00983056_m1 (N-cadherin),
Hs00365052_m1 (fibronectin), and P/N 4319413E (18S). The 18S
data were used for normalizing BIM. Quantitative real-time PCR
reactions were performed as previously described (Atilla-Gokcumen
et al., 2008).
Statistical analysis
Unless otherwise stated, all experiments were performed at least
three times. Data show mean values±SEM. Significance was analyzed
using a Student’s t-test with Po0.05 being considered significant.
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